US regulatory status: approved. Molecular target: Prostaglandin E2 receptor EP1 subtype.
- Target
- Prostaglandin E2 receptor EP1 subtype
- Mechanism
- Prostanoid EP1 receptor agonist
biotech · Coronary Artery Disease · Bronchopulmonary Dysplasia · ASBP
Aspire Biopharma Holdings
Aspire Biopharma Holdings drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Humacao, USA HQ
2019 Founded
Public company Type
ASBP · NYSE Ticker
Company details
- Status
- Public
- HQ
- Humacao, USA
- Founded
- 2019
- Programs
- 8
- Drugs
- 8
- Patents
- 1
Aspire Biopharma Holdings pipeline
Portfolio lens on 8 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Aspire Biopharma Holdings drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Aspire Biopharma Holdings in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI.
- Target
- Enoyl-[acyl-carrier-protein] reductase [NADH] FabI
- Mechanism
- Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor
-
US regulatory status: approved.
-
regadenoson
Cardiovascular system (C01)US regulatory status: approved. Molecular target: Adenosine receptor A2a.
- Target
- Adenosine receptor A2a
- Mechanism
- Adenosine A2a receptor agonist
-
Development asset linked to Aspire Biopharma Holdings in public FDA and regional records.
-
ulipristal acetate
Genito-urinary system and sex hormones (G03)US regulatory status: approved. Molecular target: Progesterone receptor.
- Target
- Progesterone receptor
- Mechanism
- Progesterone receptor modulator
-
US regulatory status: approved.